SELLAS Life Sciences Group, Inc. (SLS)
7.87
-0.16
(-1.99%)
USD |
NASDAQ |
Nov 13, 16:00
7.80
-0.07
(-0.89%)
After-Hours: 19:59
SELLAS Life Sciences Group Enterprise Value : 1.484B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 1.484B |
| November 11, 2026 | 1.562B |
| November 10, 2026 | 1.552B |
| November 09, 2026 | 1.595B |
| November 06, 2026 | 1.562B |
| November 05, 2026 | 1.453B |
| November 04, 2026 | 1.708B |
| November 03, 2026 | 1.653B |
| November 02, 2026 | 1.589B |
| October 30, 2026 | 1.817B |
| October 29, 2026 | 1.913B |
| October 28, 2026 | 1.958B |
| October 27, 2026 | 2.320B |
| October 26, 2026 | 2.152B |
| October 23, 2026 | 2.192B |
| October 22, 2026 | 2.154B |
| October 21, 2026 | 2.314B |
| October 20, 2026 | 2.281B |
| October 19, 2026 | 1.980B |
| October 16, 2026 | 1.877B |
| October 15, 2026 | 2.152B |
| October 14, 2026 | 2.261B |
| October 13, 2026 | 2.368B |
| October 12, 2026 | 2.271B |
| October 09, 2026 | 2.215B |
| Date | Value |
|---|---|
| October 08, 2026 | 2.136B |
| October 07, 2026 | 2.146B |
| October 06, 2026 | 2.152B |
| October 05, 2026 | 2.211B |
| October 02, 2026 | 2.233B |
| October 01, 2026 | 2.150B |
| September 30, 2026 | 2.348B |
| September 29, 2026 | 2.186B |
| September 28, 2026 | 2.203B |
| September 25, 2026 | 2.207B |
| September 24, 2026 | 2.281B |
| September 23, 2026 | 2.188B |
| September 22, 2026 | 2.289B |
| September 21, 2026 | 2.158B |
| September 18, 2026 | 2.182B |
| September 17, 2026 | 2.190B |
| September 16, 2026 | 2.217B |
| September 15, 2026 | 2.142B |
| September 14, 2026 | 2.230B |
| September 11, 2026 | 2.193B |
| September 10, 2026 | 2.586B |
| September 09, 2026 | 2.679B |
| September 08, 2026 | 2.681B |
| September 04, 2026 | 2.661B |
| September 03, 2026 | 2.629B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 590.62B |
| ImmunityBio, Inc. | 7.420B |
| TG Therapeutics, Inc. | 10.01B |
| Capricor Therapeutics, Inc. | 489.99M |
| Relay Therapeutics, Inc. | 3.147B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.605M |
| Total Expenses (Quarterly) | 9.605M |
| EPS Diluted (Quarterly) | -0.0508 |
| Earnings Yield | -2.69% |
| Normalized Earnings Yield | -2.696 |